639 related articles for article (PubMed ID: 16330673)
21. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
22. EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
Liu B; Pang B; Wang Q; Yang S; Gao T; Ding Q; Liu H; Yang Y; Fan H; Zhang R; Xin T; Xu G; Pang Q
Hum Pathol; 2017 Aug; 66():101-107. PubMed ID: 28666925
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.
Panousis D; Xepapadakis G; Lagoudianakis E; Karavitis G; Salemis N; Koronakis N; Patsouris E; Koronarchis D; Grosomanidis D; Chryssikos G; Ntasiou P; Kyriakidou V; Athanassiadou AM; Athanassiadou P
J BUON; 2013; 18(4):879-85. PubMed ID: 24344012
[TBL] [Abstract][Full Text] [Related]
24. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
25. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
26. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
27. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
28. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
[TBL] [Abstract][Full Text] [Related]
29. Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery.
Li K; Chen MK; Situ J; Huang WT; Su ZL; He D; Gao X
Chin Med J (Engl); 2013 Jan; 126(1):82-7. PubMed ID: 23286483
[TBL] [Abstract][Full Text] [Related]
30. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
32. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
Laitinen S; Martikainen PM; Tolonen T; Isola J; Tammela TL; Visakorpi T
Int J Cancer; 2008 Feb; 122(3):595-602. PubMed ID: 17943722
[TBL] [Abstract][Full Text] [Related]
33. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.
Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S
World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530
[TBL] [Abstract][Full Text] [Related]
34. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
35. Expression of polycomb group protein EZH2 in nevi and melanoma.
McHugh JB; Fullen DR; Ma L; Kleer CG; Su LD
J Cutan Pathol; 2007 Aug; 34(8):597-600. PubMed ID: 17640228
[TBL] [Abstract][Full Text] [Related]
36. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma].
Guo ZL; Chen K; Wang XQ; Hu W
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
38. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
[TBL] [Abstract][Full Text] [Related]
39. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
[TBL] [Abstract][Full Text] [Related]
40. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
Wang X; Hu B; Shen H; Zhou H; Xue X; Chen Y; Chen S; Han Y; Yuan B; Zhao H; Zhi Q; Kuang Y
Biomed Pharmacother; 2015 Oct; 75():218-25. PubMed ID: 26271144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
